[Federal Register Volume 69, Number 233 (Monday, December 6, 2004)]
[Notices]
[Page 70470]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-26735]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importation of Controlled Substances; Notice of Application

    Pursuant to 21 U.S.C. 958(1)), the Attorney General shall, prior to 
issuing a registration under this Section to a bulk manufacturer of a 
controlled substance in Schedule I or II and prior to issuing a 
registration under 21 U.S.C. 952 (a)(2)(b) authorizing the importation 
of such substances, provide manufacturers holding registrations for the 
bulk manufacture of the substances an opportunity for a hearing.
    Therefore, in accordance with 21 CFR 1301.34(a), this is notice 
that on September 20, 2004, Johnson Matthey Inc., Pharmaceutical 
Materials, 2003 Nolte Drive, West Deptford, New Jersey 08066, made 
application by renewal to the Drug Enforcement Administration (DEA) for 
registration as an importer of the basic classes of controlled 
substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Phenylacetone (8501).......................  II
Raw Opium (9600)...........................  II
Concentrate of Poppy Straw (9670)..........  II
------------------------------------------------------------------------

    The company plans to import the listed controlled substances as raw 
materials for use in the manufacture of bulk controlled substances for 
distribution to its customers.
    Any manufacturer who is presently, or is applying to be, registered 
with DEA to manufacture such basic classes of controlled substances may 
file written comments or objections to the issuance of the proposed 
registration and may, at the same time, file a written request for a 
hearing on such application pursuant to 21 CFR 1301.43 and in such form 
as prescribed by 21 CFR 1316.47.
    Any such comments or objections or requests for hearing may be 
addressed, in quintuplicate, to the Deputy Assistant Administrator, 
Office of Diversion Control, Drug Enforcement Administration, United 
States Department of Justice, Washington, DC 20537, Attention: DEA 
Federal Register Representative, Office of Liaison and Policy (ODLR) 
and must be filed no later than January 5, 2005.
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 1301.34(b), (c), (d), 
(e), and (f). As noted in a previous notice published in the Federal 
Register on September 23, 1975, (40 FR 43745-46), all applicants for 
registration to import basic class of any controlled substance in 
Schedule I or II are and will continue to be required to demonstrate to 
the Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration that the requirements for such registration 
pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), 
(c), (d), (e), and (f) are satisfied.

    Dated: November 22, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 04-26735 Filed 12-3-04; 8:45 am]
BILLING CODE 4410-09-P